# Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

> **NCT01593332** · PHASE4 · COMPLETED · sponsor: **Mashhad University of Medical Sciences** · enrollment: 44 (actual)

## Conditions studied

- DMARD Resistant Rheumatoid Arthritis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01593332
- **Lead sponsor:** Mashhad University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593332, "Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT01593332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*